Design and baseline characteristics of participants in the researching cardiovascular events with a weekly incretin in diabetes (REWIND) trial on the cardiovascular effects of dulaglutide
Diabetes Obes Metab
; 20(1): 42-49, 2018. tab
Artigo
em Inglês
| Sec. Est. Saúde SP, SESSP-IDPCPROD, Sec. Est. Saúde SP
| ID: biblio-1062381
Biblioteca responsável:
BR79.1
Localização: BR79.1
ABSTRACT
The aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human glucagon-like peptide 1 analogue that lowers blood glucose, body weight, appetite and blood pressure, on cardiovascular outcomes. People with type 2 diabetes, aged ≥50 years, with glycated haemoglobin (HbA1c) ≤9.5%, and either a previous cardiovascular event, evidence of cardiovascular disease or ≥2 cardiovascular risk factors were randomly allocated to a weekly subcutaneous injection of either dulaglutide (1.5 mg) or placebo and followed within the ongoing Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial every 3 to 6 months. The primary cardiovascular outcome is the first occurrence of the composite of cardiovascular death or non-fatal myocardial infarction or non-fatal stroke. Secondary outcomes include each component of the primary composite cardiovascular outcome, a composite clinical microvascular outcome comprising retinal or renal disease, hospitalization for unstable angina, heart failure requiring hospitalization or an urgent heart failure visit, and all-cause mortality. Follow-up will continue until the accrual of 1200 confirmed primary outcomes...
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Brasil
Base de dados:
Sec. Est. Saúde SP
/
SESSP-IDPCPROD
Assunto principal:
Doenças Cardiovasculares
/
Diabetes Mellitus
Tipo de estudo:
Ensaio clínico controlado
/
Fatores de risco
Idioma:
Inglês
Revista:
Diabetes Obes Metab
Ano de publicação:
2018
Tipo de documento:
Artigo
Instituição/País de afiliação:
Department of Medicine and Population Health Research Institute, McMaster University and Hamilton Health Sciences/CA
/
Department of Medicine, Oregon Health & Science University Portland/US
/
Department of Medicine, University of Washington/US
/
ECLA Academic Research Organization and ICR Instituto Cardiovascular de Rosario/AR
/
Eli Lilly and Company/US
/
Endocrinology and Nutrition Department, Hospital Clínic i Universitari/ES
/
Instituto Dante Pazzanese de Cardiologia/BR
/
Karolinska Institute/SE
/
Medical University of South Carolina/US
/
St. John's Research Institute/IN